Search clinical trials for: TAK-981 Cetuximab

Total 7988 results

Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet

Japanese Healthy Adult Male

Japan
Takeda

Completed

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

Dose Finding Study
Takeda
Takeda Development Center Americas, Inc.

Terminated

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Crohn Disease

United States, Germany, Austria, France, United Kingdom
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-105 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-079 in People With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Spain, Canada, Serbia, Italy, Poland
Takeda

Completed

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Healthy Volunteers

United States
National Cancer Institute (NCI)

Not yet recruiting

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory High Risk Myelodysplastic Syndrome
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Healthy

United States
Fuji Yakuhin Co., Ltd.

Completed

Study of FYU-981 in Hyperuricemia With or Without Gout

Hyperuricemia

Japan
Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

United States
Takeda

Completed

TAK-114 Single- and Multiple-Dose Phase 1 Study

Clinical Pharmacology

Japan
AZ-VUB

Unknown

Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients

Diabetes Mellitus, Type 1

Belgium
NeuroBo Pharmaceuticals Inc.
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathy

Diabetic Neuropathy

United States
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathic Pain

Diabetic Neuropathies

Korea, Republic of
Akros Pharma Inc.

Completed

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

Anemia of Chronic Kidney Disease

United States
Samsung Bioepis Co., Ltd.

Completed

A Phase I Study of SB26 in Healthy Volunteers

Healthy Volunteers

United States
Takeda

Completed

Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults

Influenza Infection
Takeda

Completed

A Study of TAK-227 in Healthy Adults

Healthy Volunteers

United States
Calithera Biosciences, Inc

Terminated

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Canada, France, United Kingdom
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

Advanced Solid Tumor and Lymphoma Malignancies

United States, Spain, Italy, United Kingdom
Calithera Biosciences, Inc

Terminated

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Advanced Nonhematological Neoplasms

Korea, Republic of, Japan, Taiwan
Takeda

Withdrawn

Bioavailability and Food Effect Study of Two Formulations of TAK-906

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Healthy Volunteers

United States
Takeda

Completed

A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954

Renal Impairment | Healthy Volunteers

Czechia, Hungary
Takeda

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

Healthy Volunteers | Hepatic Impairment

Czechia, Slovakia
Takeda

Completed

A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants

Healthy Participants

China
Millennium Pharmaceuticals, Inc.

Completed

A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies

Carcinoma, Basal Cell | Advanced Nonhematologic Malignancies

United States
Takeda

Terminated

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus
Takeda

Recruiting

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Takeda

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Narcolepsy Type 1 | Narcolepsy Type 2

Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
Takeda
Takeda Development Center Americas, Inc.

Recruiting

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer

Unresectable Locally Advanced or Metastatic Cancer

Spain, United States, Australia, Canada
Takeda

Active, not recruiting

A Study of TAK-102 in Adult With Previously-Treated Solid Tumors

Solid Tumors

Japan
Takeda

Completed

A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Coronavirus Disease (COVID-19)

Japan
Calithera Biosciences, Inc

Withdrawn

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Lymphoma, Malignant | Advanced Solid Neoplasms

United States
Calithera Biosciences, Inc

Terminated

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Lymphoma, Non-Hodgkin | Lymphoma, Follicular, Marginal Zone

Korea, Republic of, Japan
Calithera Biosciences, Inc

Terminated

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
Takeda

Completed

Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Prostate Cancer

United States
Millennium Pharmaceuticals, Inc.

Terminated

Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies

Advanced Nonhematological Malignancies

United States
Takeda

Completed

Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis

Erosive Esophagitis

Japan
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Metastatic Melanoma | Advanced Non-hematologic Malignancies

United States
Takeda

Terminated

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

Diabetic Neuropathies
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Advanced Solid Tumors

United States
Takeda

Completed

Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2
Millennium Pharmaceuticals, Inc.

Completed

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Solid Tumors

United States

3

Subscribe